{"filing":{"accession_number":"0001140361-26-028092","cik":"0000874015","ticker":"IONS","company_name":"IONIS PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"ef20077664_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036126028092/ef20077664_8k.htm"},"events":[{"id":17206,"run_id":15392,"accession_number":"0001140361-26-028092","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Ionis announced that its Phase 3 CARDIO-TTRansform trial for eplontersen failed to meet its primary efficacy endpoint of composite cardiovascular mortality and recurrent cardiovascular events in ATTR-CM patients, though a nominally significant result was observed in a prespecified monotherapy subgroup. This represents a material clinical trial failure for a key pipeline asset that significantly impacts the company's commercial prospects and strategic direction in ATTR-CM treatment.","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15574,"accession_number":"0001140361-26-028092","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces that the CARDIO-TTRansform Phase 3 trial for eplontersen \"did not meet the primary efficacy endpoint\" in ATTR-CM patients. This is a material clinical trial failure for a key pipeline asset in development, representing a significant operational and strategic setback. While not a restatement, going-concern issue, or other specific terminal event, the failure of a major Phase 3 trial is a material operational event that would affect investor assessment of the company's pipeline value and near-term commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:04:20.159681+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15575,"accession_number":"0001140361-26-028092","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Ionis announced that its Phase 3 CARDIO-TTRansform trial for eplontersen failed to meet its primary efficacy endpoint of composite CV mortality and recurrent CV events, though a nominally significant result was observed in a prespecified monotherapy subgroup. This is a material clinical trial failure for a key pipeline asset in development, affecting the company's commercial prospects and strategic direction in ATTR-CM treatment. While not a completed M\u0026A, restatement, or financial obligation event, the failure of a major Phase 3 trial is a material operational/clinical development event that would significantly impact investor assessment of the registrant's pipeline value and future revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:04:20.159681+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15574,"accession_number":"0001140361-26-028092","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces that the CARDIO-TTRansform Phase 3 trial for eplontersen \"did not meet the primary efficacy endpoint\" in ATTR-CM patients. This is a material clinical trial failure for a key pipeline asset in development, representing a significant operational and strategic setback. While not a restatement, going-concern issue, or other specific terminal event, the failure of a major Phase 3 trial is a material operational event that would affect investor assessment of the company's pipeline value and near-term commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:04:20.159681+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-07-09"},{"id":15575,"accession_number":"0001140361-26-028092","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Ionis announced that its Phase 3 CARDIO-TTRansform trial for eplontersen failed to meet its primary efficacy endpoint of composite CV mortality and recurrent CV events, though a nominally significant result was observed in a prespecified monotherapy subgroup. This is a material clinical trial failure for a key pipeline asset in development, affecting the company's commercial prospects and strategic direction in ATTR-CM treatment. While not a completed M\u0026A, restatement, or financial obligation event, the failure of a major Phase 3 trial is a material operational/clinical development event that would significantly impact investor assessment of the registrant's pipeline value and future revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T13:04:20.159681+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-07-09"}]}